Stonebridge Marble Hill | |
702 Highway 34 West, Marble Hill, Missouri 63764 | |
(573) 238-2614 | |
Name | Stonebridge Marble Hill |
---|---|
Location | 702 Highway 34 West, Marble Hill, Missouri |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 98 |
Occupancy Rate | 73.67% |
Medicare ID (CCN) | 265553 |
Legal Business Name | Eldercare Of Marble Hill, Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1902803232 |
Organization Name | ELDERCARE OF MARBLE HILL, LLC |
Doing Business As | STONEBRIDGE MARBLE HILL |
Address | 702 Highway 34 W, Marble Hill, MO 63764 |
Phone Number | 573-238-2614 |
News Archive
Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF's partnership with Osiris for the development of a therapy for type 1 diabetes.
Schering-Plough Corporation today announced the start of patient enrollment in RED-CABG, the Phase 3 Trial for acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA). Acadesine was licensed from PeriCor Therapeutics, Inc., a privately held specialty biopharmaceutical company.
St. Jude Medical, Inc., a global medical device company, today announced CE Mark approval of expanded labelling for its Ellipse implantable cardioverter defibrillator (ICD), in addition to its Durata and Optisure defibrillation leads, allowing existing or future patients with these technologies to undergo magnetic resonance imaging (MRI) scans without compromising device performance.
The Affordable Care Act allowed millions of young adults to retain health care coverage through their parents' insurance plans, but new research finds that many young African-American and Hispanic adults who need coverage for trauma care may not get it.
› Verified 6 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF's partnership with Osiris for the development of a therapy for type 1 diabetes.
Schering-Plough Corporation today announced the start of patient enrollment in RED-CABG, the Phase 3 Trial for acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA). Acadesine was licensed from PeriCor Therapeutics, Inc., a privately held specialty biopharmaceutical company.
St. Jude Medical, Inc., a global medical device company, today announced CE Mark approval of expanded labelling for its Ellipse implantable cardioverter defibrillator (ICD), in addition to its Durata and Optisure defibrillation leads, allowing existing or future patients with these technologies to undergo magnetic resonance imaging (MRI) scans without compromising device performance.
The Affordable Care Act allowed millions of young adults to retain health care coverage through their parents' insurance plans, but new research finds that many young African-American and Hispanic adults who need coverage for trauma care may not get it.
› Verified 6 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 12.93 | 14.46 |
Percentage of long-stay residents who lose too much weight | 13.49 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 30.26 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.36 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 4.17 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0.68 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 6.17 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 50.97 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 16.92 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 8.33 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 16.26 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 30.62 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 13.89 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 92.93 | 95.98 |
Percentage of short-stay residents who made improvements in function | 58.73 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 11.02 | 82.93 |
News Archive
Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF's partnership with Osiris for the development of a therapy for type 1 diabetes.
Schering-Plough Corporation today announced the start of patient enrollment in RED-CABG, the Phase 3 Trial for acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA). Acadesine was licensed from PeriCor Therapeutics, Inc., a privately held specialty biopharmaceutical company.
St. Jude Medical, Inc., a global medical device company, today announced CE Mark approval of expanded labelling for its Ellipse implantable cardioverter defibrillator (ICD), in addition to its Durata and Optisure defibrillation leads, allowing existing or future patients with these technologies to undergo magnetic resonance imaging (MRI) scans without compromising device performance.
The Affordable Care Act allowed millions of young adults to retain health care coverage through their parents' insurance plans, but new research finds that many young African-American and Hispanic adults who need coverage for trauma care may not get it.
› Verified 6 days ago
Stonebridge Marble Hill Location: 702 Highway 34 West, Marble Hill, Missouri 63764 Phone: (573) 238-2614 |